Clinical trials: HIP AND KNEE OSTEOARTHRITIS
Osteoarthritis, Knee, Osteoarthritis, Hip
Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip
The primary objective of the study is to evaluate the efficacy of fasinumab compared to placebo, when administered for up to 24 weeks in patients with pain due to osteoarthritis (OA) of the knee or hip.
- Trial name
- FACT OA2 (NCT03304379)
- Testing
- Fasinumab, Diclofenac, Celecoxib
- Where
- 71 sites in United States
- Volunteers
- 1,650 people
- Sponsor
- Regeneron Pharmaceuticals
Osteoarthritis
52 Week, International, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Clinical Trial to Compare Retention on Treatment, Safety, Tolerability & Efficacy of Lumiracoxib 100 mg od, Lumiracoxib 100 mg Bid & Celecoxib 200 mg od in Pts With Primary OA of Hip, Knee, Hand or Spine
This trial will compare the retention on treatment (based on the rate of patients staying on treatment for 1 year) of patients suffering from primary osteoarthritis using two different doses of lumiracoxib (100 mg od or 100 mg…
- Trial name
- NCT00145301
- Testing
- Lumiracoxib
- Where
- Germany
- Volunteers
- 3,036 people
- Sponsor
- Novartis
Osteoarthritis
A Study of the Safety and Effectiveness of Orally Administered CR845 in Patients With Osteoarthritis of the Hip or Knee
To assess the safety and tolerability of orally-administered CR845 in patients with osteoarthritis (OA) of the hip or knee. The study drug is being tested to reduce OA pain, and will be taken twice a day for two weeks, with four…
- Trial name
- NCT02524197
- Testing
- CR845 0.25 mg, CR845 0.50 mg, CR845 1 mg
- Where
- 5 sites in United States
- Volunteers
- 81 people
- Sponsor
- Cara Therapeutics, Inc.
Osteoarthritis
A Study to Assess Etoricoxib Versus Diclofenac in Chinese Patients With Osteoarthritis of the Knee or Hip (0663-080)(COMPLETED)
A Study to Assess Etoricoxib versus Diclofenac in Chinese Patients with Osteoarthritis of the Knee or Hip
- Trial name
- NCT00140972
- Testing
- MK0663; etoricoxib / Duration of Treatment:4 Weeks, Comparator: diclofenac sodium tablet 75 mg / Duration of Treatment:4 Weeks
- Volunteers
- 160 people
- Sponsor
- Organon and Co
Osteoarthritis, Knee, Osteoarthritis, Hip
An Effectiveness, Safety and Quality of Life Measures With Hydromorphone HCL, Dilaudid CR (Controlled Release)
The purpose of this study was to characterize the effectiveness and safety of OROS hydromorphone HCL and OxyContin in patients with chronic osteoarthritis (OA) of the knee or hip who are receiving chronic nonsteroidal…
- Trial name
- NCT00399048
- Testing
- OROS hydromorphone HCL ; OxyContin
- Volunteers
- 140 people
- Sponsor
- Alza Corporation, DE, USA
Osteoarthritis
Long-term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee, Hip or Shoulder Replacement
A4091064 is a multicenter, long-term observational study of subjects from tanezumab interventional studies (regardless of treatment group) who undergo a total knee, hip or shoulder replacement during participation in the study.
- Trial name
- NCT02674386
- Testing
- Investigational Medical Product (IMP) administered in parent study
- Where
- 79 sites in United States, Australia and 13 more
- Volunteers
- 154 people
- Sponsor
- Pfizer
Osteoarthritis
Tanezumab in Osteoarthritis of the Hip or Knee (2)
Test the efficacy and safety of 2 doses of tanezumab compared with naproxen and placebo in patients with osteoarthritis
- Trial name
- NCT00863304
- Testing
- tanezumab 10 mg, tanezumab 5 mg, naproxen
- Where
- 95 sites in United States
- Volunteers
- 849 people
- Sponsor
- Pfizer
Osteoarthritis
Safety and Efficacy of the Buprenorphine Transdermal Delivery System in Subjects With Osteoarthritis Pain.
The objective of this study is to assess the safety and efficacy of the buprenorphine transdermal system (5, 10, and 20 mg) in comparison to placebo transdermal system in subjects with osteoarthritis pain.
- Trial name
- NCT00314652
- Testing
- Buprenorphine transdermal delivery system
- Where
- 22 sites in United States
- Volunteers
- 260 people
- Sponsor
- Purdue Pharma LP
Osteoarthritis
Long-Term Study Of The Safety Of Tanezumab In Arthritis Patients
Tanezumab, administered for up to 1 1/2 years, reduces the pain of osteoarthritis without affecting how nerve impulses are transmitted in sensory nerves
- Trial name
- NCT00960804
- Testing
- Tanezumab
- Where
- 18 sites in United States
- Volunteers
- 21 people
- Sponsor
- Pfizer
Pain, Osteoarthritis, Hip
Placebo-controlled Trial With OROS Hydromorphone Hydrochloride to Treat Patients With Moderate to Severe Pain Induced by Osteoarthritis of the Hip or the Knee
This clinical trial tests the pain relieving effectiveness of OROS hydromorphone, a once-daily formulation of a strong opioid against placebo in patients, who are suffering from pain due to osteoarthritis of the hip or the knee…
- Conditions
- Pain, Osteoarthritis, Hip, Osteoarthritis, Knee
- Trial name
- NCT00980798
- Testing
- OROS hydromorphone HCl
- Where
- 12 sites in Czechia, Romania and 2 more
- Volunteers
- 288 people
- Sponsor
- Janssen-Cilag International NV
Pain, Osteoarthritis
Comparison of BTDS (Buprenorphine Transdermal System) and Placebo in Osteoarthritic Pain
The primary objective of this study is to evaluate the efficacy and safety of BTDS compared to placebo in subjects with moderate to severe osteoarthritic pain of the hip or knee.
- Trial name
- NCT00345787
- Testing
- Buprenorphine Transdermal System
- Where
- 28 sites in Japan
- Volunteers
- 262 people
- Sponsor
- Mundipharma K.K.
Osteoarthritis of the Knee or Hip
Long-Term Safety and Efficacy Study of Fasinumab in Patients With Pain Due to Osteoarthritis (OA) of the Knee or Hip
The primary objective of the study is to describe the safety and tolerability of fasinumab, including adverse events of special interest (AESIs), in patients with pain due to radiographically-confirmed OA of the knee or hip.
- Trial name
- FACT LTS & OA (NCT02683239)
- Testing
- Fasinumab
- Where
- 149 sites in United States, Bulgaria and 19 more
- Volunteers
- 5,331 people
- Sponsor
- Regeneron Pharmaceuticals
Osteoarthritis
Safety of BTDS in Subjects With Osteoarthritic (OA) Pain of Hip or Knee: A 6-Month Open-label Extension Phase
The purpose of the extension phase is to evaluate the long-term safety and tolerability of buprenorphine transdermal system (BTDS).
- Trial name
- NCT01141283
- Testing
- Buprenorphine transdermal patch
- Where
- 42 sites in United States
- Volunteers
- 290 people
- Sponsor
- Purdue Pharma LP
Osteoarthritis
Extension Study Of Tanezumab In Osteoarthritis
Safety extension study of Phase 3 Osteoarthritis trials with Tanezumab
- Trial name
- NCT00809783
- Testing
- tanezumab
- Where
- 226 sites in United States
- Volunteers
- 2,147 people
- Sponsor
- Pfizer
Osteoarthritis
Safety and Efficacy of Buprenorphine Transdermal System in Subjects With Moderate to Severe Osteoarthritis of Hip or Knee
The objective of this study is to demonstrate the effectiveness and tolerability of the buprenorphine transdermal system (BTDS) (5, 10 and 20) in comparison to placebo transdermal system in subjects with moderate to severe…
- Trial name
- NCT00313846
- Testing
- Buprenorphine transdermal patch
- Where
- 44 sites in United States
- Volunteers
- 529 people
- Sponsor
- Purdue Pharma LP
Osteoarthritis Pain of the Hip and or Knee
Norspan Efficacy and Safety Among Elderly Subjects
An open label, multi-centre, prospective age-group-controlled study to evaluate efficacy and safety of buprenorphine transdermal patches in subjects with chronic, moderate to severe osteoarthritis pain of the hip and/or knee.
- Trial name
- NCT01276431
- Testing
- Buprenorphine transdermal patch
- Where
- 2 sites in Sweden
- Volunteers
- 102 people
- Sponsor
- Mundipharma AB
Osteoarthritis, Knee, Osteoarthritis, Hip
Open Label Safety and Tolerability Study of COV155 in Subjects With Osteoarthritis (OA) or Chronic Low Back Pain (CLBP)
A study to show the safety of COV155 in patients with osteoarthritis of the knee or hip or moderate to severe chronic low back pain.
- Conditions
- Osteoarthritis, Knee, Osteoarthritis, Hip, Chronic Low Back Pain
- Trial name
- NCT01722864
- Testing
- COV155
- Where
- 34 sites in United States
- Volunteers
- 153 people
- Sponsor
- Mallinckrodt
Pain, Activities of Daily Living
A Double-blind, Randomized, Parallel Group, Fase III Comparative Study With Rose Hip Powder Powder and Placebo Given to Patients With Mild to Moderate Osteoarthritis in the Knee or/and Hip
The trial is an investigator-initiated, double-blind, randomized, placebo-controlled phase III study. After the patient has receiving information about the study and after given written informed consent, the patient will be…
- Conditions
- Pain, Activities of Daily Living, Quality of Life
- Trial name
- NCT01459939
- Testing
- Rose-hip powder capsules
- Where
- Denmark
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Hyben Vital ApS
Osteoarthritis, Hip, Osteoarthritis, Knee
A Safety and Effectiveness Study of Acetaminophen (4000 mg/Day) and Naproxen (750 mg/Day) in the Treatment of Osteoarthritis of the Hip or Knee
The purpose of this study is to compare the long-term safety and effectiveness of acetaminophen (4000 mg per day) and naproxen (750 mg per day) in the treatment of osteoarthritis of the hip or knee.
- Trial name
- NCT00240773
- Testing
- acetaminophen, naproxen
- Volunteers
- 581 people
- Sponsor
- Johnson & Johnson Consumer and Personal Products Worldwide
Pain, Physical Function
Osteoarthritis Outcomes in Different Ages
We aim to study if there are differences in outcomes between different age groups for persons with knee or hip osteoarthritis during treatment in digitally delivered exercise and education treatment.
- Conditions
- Pain, Physical Function, Age
- Trial name
- NCT05208463
- Testing
- Joint Academy
- Where
- Sweden
- Volunteers
- 14,610 people
- Sponsor
- Joint Academy